A Novel Signature Based on Angiogenesis-Related Genes Predicts the Prognosis and Immunotherapy Response in HER2-Positive Breast Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2024 Jul 15

PMID 39006091

Authors

Shuanglong Chen

Weiheng Cui

Jiale Dong

Wenyan Chen

Hongmei Dong

Ruijun Zhao

Affiliations

Soon will be listed here.

Abstract

HER2-positive breast cancer is one of the most prevalent subtypes of breast cancer and represents a significant health concern for women worldwide due to its high morbidity and mortality rates. Recent studies have consistently underscored the pivotal role of angiogenesis in the development and progression of HER2-positive breast cancer. Here, we developed a prognostic signature based on angiogenesis-related genes (ARGs) to categorize HER2-positive breast cancer patients and provide insights into their survival outcomes. Kaplan-Meier survival curve, time-dependent receiver operating characteristic (ROC) and nomogram were performed to investigate the prognostic performance of the signature. In addition, we comprehensively analyzed the correlation of the prognostic signature with immune cell infiltration, immune checkpoint inhibitors (ICIs) therapy. Finally, Immunohistochemistry (IHC) and immunoblotting were used to investigate XBP1 expression in HER2-positive breast cancer tissues. Colony formation assay was performed to examine cell proliferation of HER2-positive breast cancer cells. The Kaplan-Meier curves and the ROC curves demonstrated that the ARGs had good performance in predicting the prognosis of HER2-positive breast cancer patients. In addition, we observed that the low-risk group was remarkably associated with immune infiltration and better response to ICIs. Further experimental results show that XBP1 is upregulated in human HER2-positive breast cancer, and its knockdown significantly inhibited cell proliferation. Our study demonstrated that the ARGs could serve as a novel biomarker for predicting the prognosis of patients with HER2-positive breast cancer and providing new insights into immunotherapy strategies for these patients.

References

Miles D, Chan A, Dirix L, Cortes J, Pivot X, Tomczak P . Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol. 2010; 28(20):3239-47. DOI: 10.1200/JCO.2008.21.6457. View

Slattery M, John E, Stern M, Herrick J, Lundgreen A, Giuliano A . Associations with growth factor genes (FGF1, FGF2, PDGFB, FGFR2, NRG2, EGF, ERBB2) with breast cancer risk and survival: the Breast Cancer Health Disparities Study. Breast Cancer Res Treat. 2013; 140(3):587-601. PMC: 3860319. DOI: 10.1007/s10549-013-2644-5. View

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

Wang X, Mao J, Zhou T, Chen X, Tu H, Ma J . Hypoxia-induced myeloid derived growth factor promotes hepatocellular carcinoma progression through remodeling tumor microenvironment. Theranostics. 2021; 11(1):209-221. PMC: 7681097. DOI: 10.7150/thno.49327. View

Baker J, Kyle A, Reinsberg S, Moosvi F, Patrick H, Cran J . Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment. Clin Exp Metastasis. 2018; 35(7):691-705. PMC: 6209006. DOI: 10.1007/s10585-018-9929-3. View

Chandler K, Costello C, Rahimi N . Glycosylation in the Tumor Microenvironment: Implications for Tumor Angiogenesis and Metastasis. Cells. 2019; 8(6). PMC: 6627046. DOI: 10.3390/cells8060544. View

Kudo M . Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma. Cancers (Basel). 2020; 12(5). PMC: 7281246. DOI: 10.3390/cancers12051089. View

Mombelli S, Cochaud S, Merrouche Y, Garbar C, Antonicelli F, Laprevotte E . IL-17A and its homologs IL-25/IL-17E recruit the c-RAF/S6 kinase pathway and the generation of pro-oncogenic LMW-E in breast cancer cells. Sci Rep. 2015; 5:11874. PMC: 4648389. DOI: 10.1038/srep11874. View

Derakhshani A, Rezaei Z, Safarpour H, Sabri M, Mir A, Sanati M . Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy. J Cell Physiol. 2019; 235(4):3142-3156. DOI: 10.1002/jcp.29216. View

10.

Luo M, Wicha M . Targeting Cancer Stem Cell Redox Metabolism to Enhance Therapy Responses. Semin Radiat Oncol. 2018; 29(1):42-54. PMC: 6614864. DOI: 10.1016/j.semradonc.2018.10.003. View

11.

Liu Q, Huang S, Desautels D, McManus K, Murphy L, Hu P . Development and validation of a prognostic 15-gene signature for stratifying HER2+/ER+ breast cancer. Comput Struct Biotechnol J. 2023; 21:2940-2949. PMC: 10196919. DOI: 10.1016/j.csbj.2023.05.002. View

12.

Zhao M, Pan X, Layman R, Lustberg M, Mrozek E, Macrae E . A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer. Invest New Drugs. 2014; 32(6):1285-94. PMC: 4303337. DOI: 10.1007/s10637-014-0122-5. View

13.

Du L, Chang H, Xu W, Wei Y, Wang Y, Yin L . Effect of NMO-IgG on the interleukin-6 cascade in astrocytes via activation of the JAK/STAT3 signaling pathway. Life Sci. 2020; 258:118217. DOI: 10.1016/j.lfs.2020.118217. View

14.

Friedman H, Prados M, Wen P, Mikkelsen T, Schiff D, Abrey L . Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009; 27(28):4733-40. DOI: 10.1200/JCO.2008.19.8721. View

15.

Rhee J, Han S, Cha Y, Ham H, Kim H, Oh D . High serum TGF-α predicts poor response to lapatinib and capecitabine in HER2-positive breast cancer. Breast Cancer Res Treat. 2010; 125(1):107-14. DOI: 10.1007/s10549-010-1200-9. View

16.

Bianchi G, Loibl S, Zamagni C, Salvagni S, Raab G, Siena S . Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer. Anticancer Drugs. 2009; 20(7):616-24. View

17.

Obeidat M, Bodoor K, Alqudah M, Masaadeh A, Barukba M, Almomani R . TIMAP Upregulation Correlates Negatively with Survival in HER2- Negative Subtypes of Breast Cancer. Asian Pac J Cancer Prev. 2021; 22(6):1899-1905. PMC: 8418848. DOI: 10.31557/APJCP.2021.22.6.1899. View

18.

Falk R, Staff A, Bradwin G, Karumanchi S, Troisi R . A prospective study of angiogenic markers and postmenopausal breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Causes Control. 2016; 27(8):1009-17. PMC: 4958123. DOI: 10.1007/s10552-016-0779-5. View

19.

Jiang Z, Chen J, Du X, Cheng H, Wang X, Dong C . IL-25 blockade inhibits metastasis in breast cancer. Protein Cell. 2016; 8(3):191-201. PMC: 5326622. DOI: 10.1007/s13238-016-0345-7. View

20.

Nascimento C, Gameiro A, Ferreira J, Correia J, Ferreira F . Diagnostic Value of VEGF-A, VEGFR-1 and VEGFR-2 in Feline Mammary Carcinoma. Cancers (Basel). 2021; 13(1). PMC: 7795286. DOI: 10.3390/cancers13010117. View